Drug:
Reaction: INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION
20250101 - 20251231
No. 1 - 100
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 1 | 25491717 |
US |
||
Gastroenteritis viral, Inappropriate schedule of product administration, |
||||
GUSELKUMAB, |
||||
| 2 | 25491755 |
US |
68 | 2 |
Inappropriate schedule of product administration, |
||||
LENALIDOMIDE, |
||||
| 3 | 25491853 |
US |
2 | |
Asthma, Inappropriate schedule of product administration, |
||||
MEPOLIZUMAB, |
||||
| 4 | 25491896 |
US |
1 | |
Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 5 | 25491977 |
US |
||
Product use issue, Inappropriate schedule of product administration, Product physical consistency issue, |
||||
CALCIPOTRIENE, |
||||
| 6 | 25492042 |
US |
75 | |
Inappropriate schedule of product administration, |
||||
UPADACITINIB, |
||||
| 7 | 25492383 |
CO |
63 | 2 |
Bile duct stenosis, Hypothyroidism, Bone pain, Abdominal pain upper, Chest pain, Eye irritation, Intervertebral disc protrusion, Ear discomfort, Pain, Irritability, Eye pain, Gait disturbance, Depressed mood, Anxiety, Treatment noncompliance, Body height decreased, Weight increased, Eye pruritus, Helicobacter infection, Dry eye, Photophobia, Inappropriate schedule of product administration, Ocular discomfort, Ocular hyperaemia, Memory impairment, Obesity, Umbilical hernia, Hiatus hernia, Hepatic steatosis, Ear pain, Malaise, Palpitations, Dizziness, Nasal congestion, Arthralgia, Headache, Fatigue, Sinusitis, Cough, Pyrexia, |
||||
VEDOLIZUMAB, |
||||
| 8 | 25492678 |
US |
||
Night sweats, Hot flush, Inappropriate schedule of product administration, |
||||
RELUGOLIX, RELUGOLIX, RAMIPRIL, AMLODIPINE BESYLATE, CLONAZEPAM, ESCITALOPRAM OXALATE, ESCITALOPRAM, MEGESTROL ACETATE, MELOXICAM, MIRTAZAPINE, |
||||
| 9 | 25492699 |
US |
74 | 1 |
Inappropriate schedule of product administration, |
||||
LENALIDOMIDE, |
||||
| 10 | 25492747 |
US |
2 | |
Kidney infection, Device infusion issue, Somnolence, Inappropriate schedule of product administration, Memory impairment, Muscular weakness, Oropharyngeal pain, Infusion site mass, Migraine, Hypersensitivity, COVID-19, Illness, Wrong technique in product usage process, Abdominal discomfort, Malaise, Fatigue, |
||||
| 11 | 25492961 |
US |
68 | 2 |
Inappropriate schedule of product administration, |
||||
SPARSENTAN, |
||||
| 12 | 25493279 |
US |
2 | |
Headache, Inappropriate schedule of product administration, |
||||
NIRAPARIB, |
||||
| 13 | 25493505 |
US |
2 | |
Loss of consciousness, Panic reaction, Stress, Inappropriate schedule of product administration, Cardiac disorder, Heart rate decreased, Hereditary angioedema, |
||||
EPINEPHRINE, ADRENALINUM, C1 ESTERASE INHIBITOR RECOMBINANT, DOCUSATE SODIUM, DOCUSATE SODIUM 100MG, POLYETHYLENE GLYCOL 3350, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, ERGOCALCIFEROL, CLONAZEPAM, BISACODYL, BISACODYL SUPPOSITORIES, BISCODYL, SUMATRIPTAN SUCCINATE, NAPROXEN, NAPROXEN SODIUM, DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE CAPSULE, LIQUID FILLED, WATER, STERILE WATER, STERILE WATER FOR INJECTION, CYCLOSPORINE, |
||||
| 14 | 25494015 |
US |
1 | |
Oropharyngeal discomfort, Adverse drug reaction, Inappropriate schedule of product administration, Product substitution issue, Blood pressure increased, Therapeutic response shortened, Therapeutic response decreased, |
||||
DESMOPRESSIN ACETATE, |
||||
| 15 | 25494073 |
43 | 2 | |
Maternal exposure during pregnancy, Sciatica, Road traffic accident, Dyspepsia, Lower limb fracture, Incorrect route of product administration, Inappropriate schedule of product administration, Overdose, |
||||
METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE, PANTOPRAZOLE, PANTOPRAZOLE, PANTOPRAZOLE, PANTOPRAZOLE, CALCIUM CARBONATE, ANTACID, CALCIUM CARBONATE, ANTACID, CALCIUM CARBONATE, ANTACID, CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, LANSOPRAZOLE, PREDNISONE, CALCIUM GLUCONATE, HYDROCHLOROTHIAZIDE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, SULFASALAZINE, |
||||
| 16 | 25494089 |
US |
2 | |
Chronic kidney disease, Atrial fibrillation, Abdominal pain upper, Epistaxis, Inappropriate schedule of product administration, Fatigue, Dizziness, Chest pain, Peripheral swelling, Burning sensation, Paraesthesia, Hypoaesthesia, Rash pruritic, Rash macular, |
||||
LENALIDOMIDE, POMALIDOMIDE, |
||||
| 17 | 25494148 |
US |
2 | |
Loss of consciousness, Polyarthritis, Ankylosing spondylitis, Von Willebrand^s disease, Intervertebral disc displacement, Pain, Fatigue, Emotional disorder, Cervicogenic headache, Spondyloarthropathy, Abdominal pain upper, White blood cell count decreased, Essential hypertension, Migraine, Anxiety disorder, Ehlers-Danlos syndrome, Concussion, Raynaud^s phenomenon, Anaemia, Abdominal pain, Gastrooesophageal reflux disease, Rhinitis allergic, Affective disorder, Sleep apnoea syndrome, Essential tremor, Behaviour disorder, Condition aggravated, Gastritis, Neck pain, Acute sinusitis, Conjunctivitis allergic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, ADALIMUMAB, |
||||
| 18 | 25494280 |
US |
1 | |
Instillation site discharge, Inappropriate schedule of product administration, |
||||
NADOFARAGENE FIRADENOVEC-VNCG, |
||||
| 19 | 25494449 |
US |
2 | |
Urticaria, Inappropriate schedule of product administration, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 20 | 25494463 |
PE |
2 | |
Pneumonia, Malaise, Inappropriate schedule of product administration, |
||||
SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, |
||||
| 21 | 25494496 |
US |
2 | |
Inappropriate schedule of product administration, |
||||
SPARSENTAN, |
||||
| 22 | 25494562 |
US |
1 | |
Inappropriate schedule of product administration, |
||||
SPARSENTAN, |
||||
| 23 | 25494612 |
US |
2 | |
Dementia, Inappropriate schedule of product administration, Product dose omission issue, |
||||
VEDOLIZUMAB, |
||||
| 24 | 25494676 |
CA |
||
Dysgeusia, Chills, Diarrhoea, Hypoglycaemia, Fatigue, Influenza, Diverticulitis, Nausea, Vomiting, Headache, Injection site rash, Injection site pruritus, Injection site erythema, Weight decreased, Intentional dose omission, Inappropriate schedule of product administration, Therapy partial responder, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, ADALIMUMAB-AATY, HYDROXYCHLOROQUINE SULFATE, CLONAZEPAM, METHOTREXATE, METHOTREXATE SODIUM, FOLIC ACID, DICLOFENAC, DICLOFENAC SODIUM, SEMAGLUTIDE, ESCITALOPRAM OXALATE, ESCITALOPRAM, SEMAGLUTIDE, |
||||
| 25 | 25494879 |
US |
||
Inappropriate schedule of product administration, |
||||
NIRMATRELVIR AND RITONAVIR, |
||||
| 26 | 25495134 |
US |
61 | 1 |
Inappropriate schedule of product administration, |
||||
CANAKINUMAB, |
||||
| 27 | 25495256 |
US |
57 | |
Inappropriate schedule of product administration, No adverse event, |
||||
LETERMOVIR, |
||||
| 28 | 25495305 |
FR |
78 | 1 |
Pleural effusion, Inappropriate schedule of product administration, |
||||
ABIRATERONE ACETATE, ABIRATERONE, PREDNISONE, DEGARELIX, |
||||
| 29 | 25495388 |
US |
30 | 2 |
Vaginal discharge, Mood swings, Abdominal pain upper, Intentional product misuse, Inappropriate schedule of product administration, |
||||
LEVONORGESTREL, |
||||
| 30 | 25495429 |
US |
2 | |
General physical health deterioration, Nausea, Vomiting, Abdominal pain upper, Inappropriate schedule of product administration, Drug tolerance decreased, |
||||
| 31 | 25495439 |
US |
1 | |
Diarrhoea, Inappropriate schedule of product administration, |
||||
| 32 | 25495569 |
US |
62 | 2 |
Petechiae, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 33 | 25495588 |
US |
52 | 2 |
Eye disorder, Condition aggravated, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 34 | 25495593 |
US |
4 | 2 |
Skin irritation, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 35 | 25495600 |
US |
28 | 1 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 36 | 25495602 |
US |
27 | |
Inappropriate schedule of product administration, |
||||
ENOXAPARIN SODIUM, |
||||
| 37 | 25495645 |
US |
22 | 1 |
Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 38 | 25495693 |
US |
73 | 2 |
Abdominal pain upper, Rash pruritic, Vision blurred, Injection site pain, Wrong technique in product usage process, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 39 | 25495695 |
US |
27 | 2 |
Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 40 | 25495735 |
US |
32 | 1 |
Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 41 | 25495737 |
US |
56 | 2 |
Asthma, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 42 | 25495760 |
US |
81 | 1 |
Pruritus, Dry skin, Illness, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 43 | 25495783 |
US |
10 | 1 |
Pain in extremity, Sleep disorder, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 44 | 25495801 |
US |
36 | 2 |
Therapeutic response decreased, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 45 | 25495802 |
US |
33 | 1 |
Diarrhoea, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 46 | 25495861 |
US |
49 | 2 |
Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 47 | 25495885 |
US |
8 | 2 |
Eczema, Pruritus, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 48 | 25495932 |
CA |
43 | 2 |
Maternal exposure timing unspecified, Exposure during pregnancy, Joint stiffness, Ear pain, Crohn^s disease, Red blood cell sedimentation rate increased, Hepatic cirrhosis, Exostosis, Drug-induced liver injury, Osteoporosis, Bronchitis, Tachycardia, Upper respiratory tract infection, Visual impairment, Ear infection, Therapy non-responder, Ulcer haemorrhage, Lupus vulgaris, Lupus-like syndrome, Frequent bowel movements, Laryngitis, C-reactive protein abnormal, Bone erosion, Feeling hot, Bursitis, Retinitis, Prescribed overdose, Inappropriate schedule of product administration, |
||||
METHOTREXATE SODIUM, METHOTREXATE SODIUM, METHOTREXATE SODIUM, METHOTREXATE SODIUM, METHOTREXATE SODIUM, METHOTREXATE SODIUM, METHOTREXATE SODIUM, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, SULFASALAZINE, RITUXIMAB, SULFASALAZINE, DESOGESTREL AND ETHINYL ESTRADIOL, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE, OXYCODONE, SECUKINUMAB, APREPITANT, ADALIMUMAB-ADAZ, DESOGESTREL AND ETHINYL ESTRADIOL, LISINOPRIL, ALBUTEROL SULFATE, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, |
||||
| 49 | 25496177 |
US |
79 | 1 |
Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 50 | 25496211 |
US |
78 | 2 |
Cellulitis, Upper respiratory tract infection, Cough, Rhinorrhoea, Sneezing, Sputum discoloured, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 51 | 25496509 |
GB |
52 | 1 |
Dental operation, Therapeutic product effect incomplete, Inappropriate schedule of product administration, |
||||
RISANKIZUMAB-RZAA, RISANKIZUMAB-RZAA, |
||||
| 52 | 25496532 |
US |
2 | |
Inappropriate schedule of product administration, Product distribution issue, Product use issue, Insurance issue, Product dose omission issue, |
||||
LANADELUMAB-FLYO, LANADELUMAB-FLYO, LANADELUMAB-FLYO, |
||||
| 53 | 25496566 |
US |
62 | 2 |
Injection site reaction, Pulmonary function test decreased, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 54 | 25490931 |
US |
38 | 2 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 55 | 25490947 |
US |
52 | 2 |
Dermatitis atopic, Inappropriate schedule of product administration, Product dose omission in error, |
||||
DUPILUMAB, |
||||
| 56 | 25490949 |
US |
59 | 2 |
Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 57 | 25490955 |
US |
24 | 2 |
Rebound eczema, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 58 | 25490959 |
US |
79 | 2 |
Pruritus, Symptom recurrence, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 59 | 25490976 |
US |
2 | |
Inappropriate schedule of product administration, Eczema, Rash, |
||||
DUPILUMAB, |
||||
| 60 | 25491118 |
US |
2 | |
Guttate psoriasis, Condition aggravated, Dermatitis atopic, Inappropriate schedule of product administration, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 61 | 25491141 |
US |
6 | 2 |
Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 62 | 25491377 |
CA |
55 | 2 |
Rash, Decreased activity, Dysstasia, Gait disturbance, General physical health deterioration, Grip strength decreased, Illness, Inappropriate schedule of product administration, Influenza, Pain, Psoriatic arthropathy, Treatment failure, Condition aggravated, |
||||
METHOTREXATE, METHOTREXATE SODIUM, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, CELECOXIB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, HYDROCORTISONE, DESOXIMETASONE, ADALIMUMAB, HYDROXYCHLOROQUINE, INFLIXIMAB, MELOXICAM, MELOXICAM, NAPROXEN, NAPROXEN SODIUM, HYDROXYCHLOROQUINE SULFATE, TRAMADOL HYDROCHLORIDE, PREDNISONE, INFLIXIMAB, SULFASALAZINE, ADALIMUMAB-ADAZ, |
||||
| 63 | 25491395 |
US |
43 | 2 |
Inappropriate schedule of product administration, Psoriasis, |
||||
IXEKIZUMAB, |
||||
| 64 | 25491415 |
US |
2 | |
Dermatitis contact, Off label use, Inappropriate schedule of product administration, Diarrhoea, |
||||
| 65 | 25491492 |
CA |
2 | |
Radiotherapy, Sepsis, Infection, Clostridium difficile colitis, Colitis, Diverticulitis, Peripheral swelling, Joint swelling, Oral pain, Gingival pain, Ear pruritus, Pruritus, Diarrhoea, Abdominal pain lower, Mucosal inflammation, Rash, Oedema, Pain, Diarrhoea, Inappropriate schedule of product administration, Diverticulitis, Poor venous access, Poor venous access, Inappropriate schedule of product administration, Palmar-plantar erythrodysaesthesia syndrome, Inappropriate schedule of product administration, Diarrhoea, Inappropriate schedule of product administration, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, ENFORTUMAB VEDOTIN, ENFORTUMAB VEDOTIN, ENFORTUMAB VEDOTIN, METHOTREXATE, METHOTREXATE SODIUM, FOLIC ACID, ROSUVASTATIN, PANTOPRAZOLE, CLOPIDOGREL, HYDROXYCHLOROQUINE, ALBUTEROL SULFATE, APIXABAN, |
||||
| 66 | 25491625 |
US |
67 | 1 |
Death, Inappropriate schedule of product administration, |
||||
BELUMOSUDIL, |
||||
| 67 | 25489983 |
US |
9 | 2 |
Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 68 | 25489998 |
US |
74 | 1 |
Extra dose administered, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 69 | 25490013 |
US |
1 | |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 70 | 25490045 |
US |
80 | 2 |
Inappropriate schedule of product administration, |
||||
ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, |
||||
| 71 | 25490146 |
US |
32 | 2 |
Intentional dose omission, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 72 | 25490281 |
US |
47 | 2 |
Pruritus, Therapeutic response shortened, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 73 | 25490301 |
US |
62 | 2 |
Inappropriate schedule of product administration, |
||||
TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, RIOCIGUAT, OXYBUTYNIN CHLORIDE, POTASSIUM CHLORIDE, MOMETASONE FUROATE AND FORMOTEROL FUMARATE DIHYDRATE, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, GABAPENTIN, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, FLUTICASONE PROPIONATE, INSULIN GLARGINE, ALBUTEROL SULFATE, METFORMIN HYDROCHLORIDE, METFORMIN, METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, METFORMIN HYDROCHLORIDE TABLET, METFORMIN HYDROCHLORIDE TABLETS, OXYGEN, 0XYGEN, ATORVASTATIN CALCIUM, |
||||
| 74 | 25490309 |
US |
74 | 1 |
Inappropriate schedule of product administration, |
||||
INSULIN GLARGINE, |
||||
| 75 | 25490326 |
GB |
1 | |
Groin abscess, Fatigue, Nausea, Dizziness, Heart rate increased, Inappropriate schedule of product administration, |
||||
USTEKINUMAB, MIRTAZAPINE, |
||||
| 76 | 25490408 |
US |
2 | |
Inappropriate schedule of product administration, |
||||
INSULIN GLARGINE, |
||||
| 77 | 25490644 |
US |
47 | 1 |
Inappropriate schedule of product administration, Overdose, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 78 | 25490675 |
US |
89 | 1 |
Inappropriate schedule of product administration, |
||||
INSULIN GLARGINE, |
||||
| 79 | 25490882 |
US |
56 | 1 |
Dermatitis atopic, Haemorrhage, Blister, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DIAZEPAM, DIAZEPAM ORAL, DIAZEPAM ORAL SOLUTION (CONCENTRATE), HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE ORAL, METHYLPREDNISOLONE, PLECANATIDE, |
||||
| 80 | 25486363 |
US |
2 | |
Mental disorder, Quality of life decreased, Feeling abnormal, Frustration tolerance decreased, Inappropriate schedule of product administration, |
||||
TERIPARATIDE, |
||||
| 81 | 25486437 |
US |
82 | 1 |
Rash, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 82 | 25486597 |
CA |
||
Abdominal pain upper, Angina pectoris, Chills, Feeling abnormal, Frequent bowel movements, Neuralgia, Pain in extremity, Clostridium difficile infection, Gastrointestinal bacterial infection, Headache, Nausea, Inappropriate schedule of product administration, Therapy non-responder, Intentional product use issue, |
||||
USTEKINUMAB, VANCOMYCIN HYDROCHLORIDE, |
||||
| 83 | 25486613 |
43 | 2 | |
Prescribed overdose, Inappropriate schedule of product administration, Maternal exposure timing unspecified, Exposure during pregnancy, Joint stiffness, Ear pain, Crohn^s disease, Red blood cell sedimentation rate increased, Hepatic cirrhosis, Exostosis, Drug-induced liver injury, Osteoporosis, Bronchitis, Tachycardia, Upper respiratory tract infection, Visual impairment, Ear infection, Therapy non-responder, Ulcer haemorrhage, Lupus vulgaris, Lupus-like syndrome, Frequent bowel movements, Laryngitis, C-reactive protein abnormal, Bone erosion, Feeling hot, Bursitis, Retinitis, |
||||
METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE, OXYCODONE, OXYCODONE HYDROCHLORIDE, OXYCODONE, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, SULFASALAZINE, SECUKINUMAB, APREPITANT, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, SULFASALAZINE, ADALIMUMAB-ADAZ, LISINOPRIL, ALBUTEROL SULFATE, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, |
||||
| 84 | 25486673 |
US |
1 | |
Headache, Cough, Respiratory tract congestion, Pyrexia, Oxygen saturation decreased, Blood pressure increased, Hypoxia, Lung disorder, Inappropriate schedule of product administration, Wrong technique in device usage process, Off label use, |
||||
TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, AMBRISENTAN, AMLODIPINE, DUPILUMAB, ALLOPURINOL, ERGOCALCIFEROL, ALBUTEROL SULFATE, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, LOSARTAN POTASSIUM, LOSARTAN, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, OXYGEN, 0XYGEN, METFORMIN HYDROCHLORIDE, METFORMIN, METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, METFORMIN HYDROCHLORIDE TABLET, METFORMIN HYDROCHLORIDE TABLETS, DIPHENHYDRAMINE HYDROCHLORIDE, GUAIFENESIN, |
||||
| 85 | 25486682 |
US |
2 | |
Retching, Inappropriate schedule of product administration, Drug ineffective, |
||||
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HCL, |
||||
| 86 | 25486786 |
US |
||
Product administration error, Inappropriate schedule of product administration, |
||||
GUSELKUMAB, |
||||
| 87 | 25486903 |
CN |
||
Aortic arteriosclerosis, Chronic obstructive pulmonary disease, Emphysema, Pleural calcification, Hepatic cyst, Infection, Blister, Inappropriate schedule of product administration, |
||||
FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, TIOTROPIUM BROMIDE, |
||||
| 88 | 25487119 |
US |
88 | 1 |
Inappropriate schedule of product administration, |
||||
LENALIDOMIDE, |
||||
| 89 | 25487138 |
US |
97 | 2 |
Death, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, DOXYCYCLINE, DOXYCYCLINE HYCLATE, AMLODIPINE, |
||||
| 90 | 25487288 |
US |
67 | 2 |
Rash erythematous, Loss of personal independence in daily activities, Decreased appetite, Pruritus, Fatigue, Product use in unapproved indication, Inappropriate schedule of product administration, Incorrect dosage administered, |
||||
RIPRETINIB, RIPRETINIB, |
||||
| 91 | 25487323 |
CA |
1 | |
Infection, Inappropriate schedule of product administration, Product dose omission issue, |
||||
HUMAN IMMUNOGLOBULIN G, HUMAN IMMUNOGLOBULIN G, WARFARIN, WARFARIN, METOPROLOL TARTRATE, METOPROLOL, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, MAGNESIUM, |
||||
| 92 | 25487377 |
US |
||
Inappropriate schedule of product administration, |
||||
| 93 | 25487381 |
DE |
50 | 2 |
Posterior reversible encephalopathy syndrome, Blood urea increased, Blood triglycerides increased, Blood cholesterol increased, Low density lipoprotein increased, High density lipoprotein decreased, Blood thyroid stimulating hormone increased, Epilepsy, Hypertensive crisis, Diarrhoea, White blood cell count increased, Mean cell haemoglobin increased, Mean cell volume increased, Platelet count decreased, Neutrophil count increased, Lymphocyte count decreased, Blood potassium increased, Blood chloride increased, Blood creatinine increased, Glomerular filtration rate decreased, Inappropriate schedule of product administration, |
||||
BEVACIZUMAB, BEVACIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, CARBOPLATIN, CARBOPLATIN, PACLITAXEL, PACLITAXEL, |
||||
| 94 | 25487428 |
US |
30 | 1 |
Inappropriate schedule of product administration, Gastrointestinal disorder, |
||||
BUDESONIDE, |
||||
| 95 | 25487575 |
US |
29 | 2 |
Inappropriate schedule of product administration, Product packaging quantity issue, Product formulation issue, |
||||
USTEKINUMAB, |
||||
| 96 | 25487665 |
US |
1 | |
Inappropriate schedule of product administration, Intentional dose omission, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 97 | 25487710 |
US |
||
Inappropriate schedule of product administration, |
||||
BUROSUMAB, BUROSUMAB, BUROSUMAB, BUROSUMAB, BUROSUMAB, BUROSUMAB, |
||||
| 98 | 25487812 |
US |
40 | 2 |
Systemic lupus erythematosus, Adverse drug reaction, Inappropriate schedule of product administration, |
||||
BELIMUMAB, |
||||
| 99 | 25487854 |
US |
||
Underdose, Inappropriate schedule of product administration, Product use in unapproved indication, |
||||
ESTRADIOL, |
||||
| 100 | 25487902 |
US |
22 | 2 |
Colitis ulcerative, Injection site mass, Inappropriate schedule of product administration, |
||||
VEDOLIZUMAB, VEDOLIZUMAB, DESOGESTREL AND ETHINYL ESTRADIOL, SUMATRIPTAN SUCCINATE, HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE ORAL, FLUOXETINE HYDROCHLORIDE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE SULFATE AND AMPHETAMINE ASPARTATE, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-07-29